Skip to main content

If New York OKs Recreational Marijuana, Unions May Become Big Business Issue

A union official told the New York Post that labor hopes to unionize “many thousands of workers” if the state legalizes recreational cannabis – a move that could affect firms trying to break into the market.

“I think there are mixed feelings over unionized labor similar to any other industry,” cannabis attorney Rob DiPisa of Cole Schotz wrote in an email  to Marijuana Business Daily.

“Since most of these businesses are startups, the concerns I’ve heard relate to the additional overhead costs (mostly for cultivators/processors) that would need to be factored into” the initial investment by a business.

DiPisa is based in New Jersey, but he is closely monitoring the cannabis developments in New York.

He noted that “we just dealt with this because the most recent version of the New Jersey bill required unionized labor.”

The Retail, Wholesale and Department Store Union represents a few hundred workers in New York’s medical marijuana program, including employees at multistate operator Vireo Health.

For its part, Vireo Health has actively supported unionization.

Vireo New York CEO Ari Hoffnung in October encouraged unionization of New York’s potential adult-use market in prepared testimony in front of a State Assembly panel.

Labor unions are increasingly becoming a part of the marijuana landscape, with unionization already happening in markets such as California, Minnesota, Washington state and Canada.

Original Article Source: https://mjbizdaily.com/new-york-recreational-marijuana-union-workers/

Comments

Popular posts from this blog

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

A Dozen US Governors Ask Congressional Leaders To Back Federal Marijuana Reform

A bipartisan coalition of 12 governors from states that have legalized medical or recreational cannabis  sent a letter to congressional leaders, asking for their support in getting a major marijuana reform bill through the U.S. House and Senate. The governors of California, Colorado, Maryland, Massachusetts, Nevada, New York, North Dakota, Oregon, Pennsylvania, Utah, Vermont and Washington state are backing  the STATES Act  – which would codify in federal law that marijuana regulations are to be left to the states instead of the federal government – while also seeking protections on banking and tax issues for the MJ industry. “The STATES Act is not about whether marijuana should be legal or illegal; it is about respecting the authority of states to act, lead and respond to the evolving needs and attitudes of their citizens,” the governors wrote. The letter also expressed support for the SAFE Banking Act , which was approved in March by a House committee. Tha...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...